本文選題：甘氨雙唑鈉 + 鼻咽癌　； 參考：《中華腫瘤防治雜志》2014年17期

【摘要】：目的:評價甘氨雙唑鈉(metronidazole amino acidum natrium,CMNa)作為放療增敏劑治療鼻咽癌的療效與安全性。方法:利用計算機檢索Cochrane Library、PubMed、EMbase、中國生物醫(yī)學文獻數(shù)據(jù)庫(CBM)、中國學術期刊全文數(shù)據(jù)庫(CNKI)、中國科技期刊數(shù)據(jù)庫(VIP)和萬方數(shù)字化期刊全文數(shù)據(jù)庫,同時配合其他檢索,收集CMNa聯(lián)合放療治療鼻咽癌的隨機對照試驗(randomized controlled trial,RCT)。按納入和排除標準篩選文獻、提取資料和質量評價后,利用RevMan 5.1軟件進行Meta分析。結果:共納入16個RCT。在近期療效方面,CMNa聯(lián)合放療對比單純放療治療鼻咽癌,患者的原發(fā)灶(OR=3.14,95%CI為2.15~4.61,P0.001)、頸部淋巴結轉移灶(OR=2.48,95%CI為1.60~3.83,P0.001)和原發(fā)灶復發(fā)(OR=3.44,95%CI為1.72~6.84,P0.001)差異均有統(tǒng)計學意義;對比單純放療療法,CMNa聯(lián)合放療療法的1(OR=4.94,95%CI為2.41~10.15,P0.001)、3(OR=2.42,95%CI為1.31~4.50,P=0.005)和5年生存率(OR=2.04,95%CI為1.1 7~3.55,P=0.010)差異也有統(tǒng)計學意義;在惡心嘔吐、白細胞降低和影響肝功能等不良反應方面,2組差異均無統(tǒng)計學意義,P0.05。結論:CMNa作為放療增敏劑治療鼻咽癌,可以改善患者的近期療效和生存率,并不增加放療的毒副作用,在臨床上具有一定的應用價值。
[Abstract]:Aim: to evaluate the efficacy and safety of metronidazole amino acidum natriumn (CMNa) as a radiosensitizer in the treatment of nasopharyngeal carcinoma (NPC). Methods: computer search was used to retrieve Cochrane Library PubMedbase, Chinese Biomedical Literature Database (CBMN), Chinese academic Journals full text Database (CNKI), Chinese Sci-tech Journals Database (VIPB) and Wanfang Digital Journal Full-text Database. A randomized controlled trial of CMNa combined with radiotherapy for nasopharyngeal carcinoma (NPC) was conducted. The literature was screened according to the inclusion and exclusion criteria, the data was extracted and the quality was evaluated. The Meta-analysis was carried out by Revman 5.1 software. Results: 16 RCTs were included. In the short-term curative effect, compared with radiotherapy alone, there were significant differences between the primary tumor OR3.1495CI 2.15V 4.61g P0.001, the cervical lymph node metastasis 2.48995 CI 1.600.83.83n P0.001) and the primary tumor recurrence OR3.44995CI 1.72m6.844p 0.001. There was significant difference between the two groups in the treatment of nasopharyngeal carcinoma (P 0.001). The results showed that there were significant differences between the two groups in the treatment of nasopharyngeal carcinoma (OR3.44995 CI = 1.72P 0.001), the cervical lymph node metastasis (OR 2.4895 CI = 1.72P 0.001, P 0.001). There was also a significant difference in CI between CMNa and CMNa combined radiotherapy (CI = 2.41 10. 15, P 0.001, P 0.001) and 5-year survival rate (OR2.04 + 95CI = 1.173.55P0.010), while there was no significant difference in adverse reactions, such as nausea and vomiting, leukopenia and influence of liver function, between the two groups (P 0.05), and the difference between the two groups was not statistically significant (P < 0.05), but there was no significant difference between the two groups in terms of adverse reactions, such as nausea and vomiting, leukopenia, and influence on liver function, and the 5-year survival rate was 1.73.55P0.010), and there was no significant difference between the two groups in terms of adverse reactions such as nausea and vomiting, leukopenia and liver function. Conclusion as a radiosensitizer, WCMNa can improve the short-term curative effect and survival rate of patients with nasopharyngeal carcinoma, and does not increase the toxicity and side effects of radiotherapy. It has certain clinical application value.
【作者單位】： 蘭州大學第一醫(yī)院耳鼻咽喉頭頸外科;
【基金】：甘肅省衛(wèi)生廳行業(yè)科技計劃(GSWST2011-06) 甘肅省中醫(yī)藥科學技術研究課題(GIK-2011-22)
【分類號】：R739.63

【相似文獻】

相關期刊論文 前10條

1 姚志仁,林世珍,翁陽;21例鼻咽癌組織中單個核細胞亞群分布的觀察與分析[J];海南醫(yī)學;1993年02期

2 張昌卿,蕭錫賓,馮凱濤,張勝樂,葉永照,陳愛楣;識別人體上皮組織基膜的CAN181抗體及其在鼻咽癌組織中的定位[J];癌癥;1991年05期

3 宋陽;王莉芬;石林;杜翠萍;;鼻咽癌組織淋巴細胞亞群的分布與分析[J];大連醫(yī)科大學學報;2010年01期

4 張捷;PCR和探針雜交法聯(lián)合檢測鼻咽癌組織中的EB病毒[J];北京醫(yī)科大學學報;1996年01期

5 余忠華,唐慰萍;人鼻咽上皮及鼻咽癌組織角蛋白的免疫組化研究[J];廣東醫(yī)學院學報;1993年Z1期

6 區(qū)大衛(wèi),蔡體育,李端,陳愛珍,簡志瀚;鼻咽癌組織提取液,前列腺素E_2,干擾素對人自然殺傷細胞功能影響的研究[J];中山大學學報(醫(yī)學科學版);1984年01期

7 趙曉明,王靜清,王萌,竇曉暉,李小敏;鼻咽癌組織中p53基因突變及與EBV感染的關系[J];中國中西醫(yī)結合耳鼻咽喉科雜志;2004年03期

8 許亮國,陳曲侯,王s閼，

本文編號：1993471